Welcome to our dedicated page for DSS news (Ticker: DSS), a resource for investors and traders seeking the latest updates and insights on DSS stock.
DSS, Inc. reports developments across a diversified operating platform that includes Product Packaging, Biotechnology, Commercial Lending, and Securities & Investment Management. Company updates commonly address packaging operations, financial results, balance-sheet actions, common-stock offerings, and regulatory or audit disclosures.
News also covers subsidiary activity such as Sentinel Brokers Company, Inc., a FINRA-registered broker-dealer with fixed income trading, equity market-making, and approval to act as an underwriter and selling group member for corporate securities offerings.
DSS (DSS) and Impact Biomedical (IBO) report that Zoar Limited has filed a Registration Statement on Form F-4 with the SEC for the previously announced proposed business combination among Impact, Zoar and certain related parties.
DSS is a significant stockholder of Impact Biomedical and views the filing as an important milestone toward completing the transaction, which DSS’s CEO says could enhance Impact’s platform, growth opportunities and potential value for DSS shareholders. The Form F-4 includes a preliminary proxy statement of Impact and a prospectus of Zoar relating to the proposed transaction and remains subject to SEC review and effectiveness.
The business combination is still contingent on several conditions, including SEC declaration of effectiveness, approval by Impact stockholders, approval of the listing of Zoar ordinary shares on NYSE American, and satisfaction or waiver of other conditions in the merger and share exchange agreement.
DSS (DSS) has launched DSS Robotics, a new business focused on AI-powered robotics and intelligent automation for enterprise operations.
DSS Robotics will offer enterprise automation services including strategic consulting, systems integration, deployment, lifecycle support and Robotics-as-a-Service (RaaS), working with technology partners to match solutions to customer environments. The company plans an AI and Robotics Innovation Center at DSS Premier Packaging’s manufacturing facility in Rochester, New York, serving as both a live operational deployment site and a customer demonstration facility. DSS expects the venture to complement its existing enterprise technology activities and support recurring services and longer-term customer relationships.
DSS (DSS) announced it will not proceed with its previously proposed public offering of common stock. The decision follows a review that found limited capacity remaining under the company’s existing shelf registration statement.
DSS said it is continuing to evaluate other capital-raising options and reiterated its focus on creating shareholder value.
DSS (DSS) has commenced a proposed public offering of its common stock, with all shares to be issued and sold by the company itself. The offering size and pricing have not yet been disclosed and completion remains subject to market conditions.
DSS plans to use the net proceeds for general corporate and working capital purposes. The common stock trades on the NYSE American under the symbol “DSS”. Aegis Capital Corp. is acting as sole book-running manager on a firm commitment basis. The transaction is being conducted under an effective Form S-3 shelf registration, with a final prospectus supplement to be filed with the SEC.
DSS (NYSE American: DSS) announced it has withdrawn its previously filed Form S-1 registration statement with the SEC. Management and the Board determined current market conditions and deal terms would not reflect the value DSS believes it is building for shareholders.
The company states the withdrawal does not change its business outlook, operating strategy, or confidence in its assets and subsidiaries. DSS will continue evaluating financing alternatives and capital markets options, while advancing strategic initiatives including the previously announced merger involving Impact Biomedical.
DSS (NYSE American: DSS) disclosed that its annual report on Form 10-K for the fiscal year ended December 31, 2025, filed March 31, 2026, includes an audit opinion from HTL International LLC containing a going concern paragraph. The company says this announcement complies with NYSE American Guide Section 610(b) and does not amend its financial statements or the 10-K for the year ended December 31, 2025.
DSS (NYSE American: DSS) interim CEO Jason Grady outlined 2025 operational progress, cost reductions and strategic moves on April 15, 2026. Key metrics: total costs down 43% to $35.2M, printed products revenue +12% to $18.1M, and Sentinel commission revenue +39%.
The letter highlights a completed spin-out (Impact BioMedical), an announced proposed reverse merger, real estate sale proceeds of $15.7M, $17.8M of long-term debt repayments and ongoing focus on improved liquidity and shareholder value.
DSS (NYSE American: DSS) closed a firm commitment underwritten public offering, generating approximately $1.0 million in gross proceeds from the sale of 900,000 shares of common stock at $1.00 per share. An underwriter overallotment option covers up to 135,000 additional shares (15%). Net proceeds are expected to be used for general corporate purposes, including working capital. The offering was made under an effective Form S-3 (No. 333-281974) declared effective November 5, 2024, and Aegis Capital Corp. acted as book-running manager.
DSS (NYSE: DSS) priced a firm commitment underwritten public offering of 900,000 shares at $1.00 per share, with expected gross proceeds of approximately $1.0 million before fees. The underwriter has a 45-day overallotment option for an additional 135,000 shares (15%).
Aggregate proceeds are expected to be about $900,000, or $1.035 million if the over-allotment is exercised. The offering is expected to close on or about February 5, 2026. Net proceeds will be used for general corporate purposes and working capital.
DSS (NYSE: DSS) announced a proposed public offering of its common stock to be sold by the company, with net proceeds intended for general corporate and working capital purposes. The offering is subject to market conditions and may not be completed on a specific timeline or at specific terms.
Aegis Capital Corp. is sole book-running manager on a firm commitment basis. The offering will be made under an effective shelf registration statement (Form S-3 No. 333-281974, declared effective Nov 5, 2024), and a final prospectus supplement and accompanying prospectus will be filed with the SEC.